European life sciences stocks rise on strong sector momentum
BioMerieux, Eurofins, Sartorius Stedim and DiaSorin rise between 2.6% and 4.2% as strong sector momentum benefits companies involved in biopharma testing.
S. peer and solid momentum across the sector. 2%. Bernstein analyst Delphine Le Louet said Charles River's strong share price performance was spilling over into the sector.
Le Louet said momentum is building in biotech and early clinical trials, which is supporting companies involved in biopharma testing. She added that the broader healthcare sector is outperforming because it is cash-rich and not very sensitive to interest rates, prompting investors to reassess allocations. 7%, among the top sectoral moves in Europe.